Dexcom CGM Improves Glycemic Control in Non-Insulin-Treated Persons With T2D

Use of Dexcom continuous glucose monitoring (CGM) over 1 year was associated with a significant reduction in HbA_1c among adults with noninsulin-treated type 2 diabetes (T2D) in a real-world US primary care registry, according to findings from a prospective multicenter analysis.¹

The data was presented at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11-14, 2026.

The registry enrolled 318 adults with noninsulin-treated T2D across 10 US primary care centers. Investigators evaluated change in HbA_1c from baseline to the last available measurement obtained between days 180 and 390. Among 171 participants included in the primary endpoint analysis, CGM use was associated with a mean HbA_1c reduction of 0.7% (95% CI, –0.8% to –0.5%).¹

The benefit appeared greatest among participants with higher baseline HbA1c values, according to subgroup analyses. Investigators also reported high adherence, with 75% of participants wearing the device at least 70% of the time.¹

"The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin,” Jake Leach, president, chief executive officer, Dexcom, said in a press release. “That growing body of evidence, combined with our continued innovation across the Dexcom portfolio, reflects our broader ambition to transform diabetes care and advance metabolic health worldwide.”²

Baseline characteristics reflected a typical primary care population with cardiometabolic risk. Participants were 54% male and 40% non-White, with a mean age of 61 years and a mean body mass index of 31 kg/m². Overall, 80% of participants had overweight or obesity. At study entry, 59.4% of participants were using metformin, 32.1% were receiving glucagon-like peptide-1-based therapy, and 29.9% were taking a sodium-glucose cotransporter-2 inhibitor.¹

The latest generation of CGM from Dexcom, the G7 was approved in 2022 and was an improved version of the G6, which had been the company's flagship CGM product since its approval in 2018.^3,4 Less than 3 years later in 2025, Dexcom announced the FDA clearance of the Dexcom G7 15-day wear, which launched in November 2025.⁵

The findings add to growing interest in extending CGM beyond insulin-treated populations, particularly in primary care settings where most adults with T2D are managed. For clinicians, the results suggest that CGM may offer value not only for medication intensification but also for reinforcing lifestyle changes, improving engagement, and identifying glycemic patterns that are not apparent from periodic laboratory testing alone.¹

The study has important limitations. The registry was prospective but nonrandomized, and investigators noted the absence of baseline blinded CGM data. Those factors limit causal inference and make it difficult to determine how much of the observed HbA_1c improvement was attributable specifically to CGM vs concurrent clinical management or behavioral change.¹

The 1-year data support further evaluation of broader CGM access for adults with noninsulin-treated T2D in routine primary care.¹

References:

1. Martens T, Herman A, Elkind-Hirsch K, et al. One-year real-world impact of Dexcom CGM on HbA1c in non-insulin-treated type 2 diabetes: Evidence from U.S. primary care registry analysis. Presented at: The Advanced Technologies and Treatments for Diabetes Conference; March 11-14, 2026; Barcelona, Spain.
2. Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026. News release. Dexcom. March 11, 2026. Accessed March 15, 2026. https://investors.dexcom.com/news/news-details/2026/Dexcom-Showcases-Breakthrough-Outcomes-for-People-With-Type-2-Diabetes-and-Product-Roadmap-at-ATTD-2026/default.aspx
3. Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S. News release. Dexcom. December 8, 2022. Accessed March 15, 2026. https://investors.dexcom.com/news/news-details/2022/Dexcom-G7-Receives-FDA-Clearance-The-Most-Accurate-Continuous-Glucose-Monitoring-System-Cleared-in-the-U.S/default.aspx
4. FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes. News release. Dexcom. March 27, 2018. Accessed March 15, 2026. https://investors.dexcom.com/news/news-details/2018/FDA-Authorizes-Marketing-of-the-New-Dexcom-G6-CGM-Eliminating-Need-for-Fingerstick-Blood-Testing-for-People-with-Diabetes/
5. Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States. News release. Dexcom. November 20, 2025. Accessed March 15, 2026. https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Continuous-Glucose-Monitoring-System-to-Launch-on-Dec--1-in-the-United-States/default.aspx